Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 4, Issue 5, Pages 446-450Publisher
AMER CHEMICAL SOC
DOI: 10.1021/ml300365k
Keywords
Retinoic acid receptor alpha; antagonist; spermatogenesis; drug property profiling
Categories
Funding
- NIH [U01-HD060479]
- Contraceptive Discovery and Development Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development [HHSN275200503400C (N01-HD-5-3400)]
- CONRAD Foundation [CIG-05\-107]
Ask authors/readers for more resources
Oral administration of a retinoic add receptor (RAR) pan-antagonist reversibly inhibits spermatogenesis. Given the importance of RAR alpha in regulating spermatogenesis, we identified two RAR alpha-selective antagonists by transactivation and transactivation competition assays and asked whether they effectively inhibit spermatogenesis. Although these two antagonists were potent in vitro, they displayed poor in vivo activity in mice when administered orally. Testicular weights were normal, and morphological analysis revealed normal spermatid alignment and sperm release. In vitro drug property analyses were performed with one of these antagonists and compared with the pan-antagonist. We showed that the discrepancies may be explained by several factors, including high plasma protein binding, faster hepatic metabolism relative to the pan-antagonist, and only moderate permeability. The condusion of poor oral bioavailability was supported by more pronounced defects in mice when the antagonist was administered intravenously versus intraperitoneally. These results are crucial for designing new RAR alpha-selective antagonists for pharmaceutical application.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available